Chemotherapy for intracranial ependymoma in adults

Gramatzki, Dorothee; Roth, Patrick; Felsberg, Jörg; Hofer, Silvia; Rushing, Elisabeth J.; Hentschel, Bettina; Westphal, Manfred; Krex, Dietmar; Simon, Matthias; Schnell, Oliver; Wick, Wolfgang; Reifenberger, Guido; Weller, Michael

doi:10.1186/s12885-016-2323-0

BMC Cancer

Table 2 Individual patient characteristics^c

From: Chemotherapy for intracranial ependymoma in adults

No.	Initial histology	WHO grade	MGMT status	Localization	Extent of resection	First-line therapy	First salvage therapy	Surgical interventions (n)	Histology at start of CT	First CT	Duration of first CT ^a	Best response	DBR^a	PFS^a	OS^a
P1	E	II	unmethyl.	infratentorial	subtotal	-	RT	3	AE	TMZ	11	SD	11	17	68^b
P1	E	II	unmethyl.	IV ventricle	subtotal	-	RT	3	AE	TMZ	11	SD	11	17	68^b
P2	E	II	unmethyl.	supratentorial	partial	RT	re-resection RT	>3	AE	PCV	18	SD	4	21	41
P2	E	II	unmethyl.	parietal	partial	RT	re-resection RT	>3	AE	PCV	18	SD	4	21	41
P3	E	II	unmethyl.	infratentorial	partial	-	re-resection	2	AE	TMZ/RT→TMZ	8	SD	29	32^b	32^b
				cerebellar			TMZ/RT→TMZ
				brainstem
				IV ventricle
P4	E	II	unmethyl.	supratentorial	partial	-	re-resection	3	E	TMZ	6	SD	2	5	5
P4	E	II	unmethyl.	III ventricle	partial	-	re-resection	3	E	TMZ	6	SD	2	5	5
P5	AE	III	n.d.	supratentorial	gross total	RT	re-resection	2	sarcoma	epirubicin	5	CR	106	131^b	131^b
				parietal						ifosfamide
				temporal
				occipital
P6	AE	III	unmethyl.	infratentorial	subtotal	RT	carboplatin	1	AE	carboplatin	5	PR	7	11	16^b
P6	AE	III	unmethyl.	IV ventricle	subtotal	RT	etoposide	1	AE	etoposide	5	PR	7	11	16^b
P7	AE	III	n.d.	supratentorial	partial	-	re-resection	>3	AE	carboplatin	1	PD	-	2	44^b
				parietal						etoposide
										vincristine
										cyclo-phosphamide
P8	AE	III	unmethyl.	infratentorial	gross	-	re-resection	>3	AE	TMZ	17	SD	21	25	80^b
P8	AE	III	unmethyl.	IV ventricle	total	-	RT	>3	AE	TMZ	17	SD	21	25	80^b
P9	AE	III	n.d.	supratentorial	biopsy	RT	re-resection	3	gliosarcoma	TMZ	9	SD	7	10	23
				frontal			TMZ
				temporal			TMZ
P10	AE	III	n.d.	infratentorial	gross	RT	TMZ	1	AE	TMZ	5	SD	31	33	101^b
P10	AE	III	n.d.	cerebellar	total	RT	TMZ	1	AE	TMZ	5	SD	31	33	101^b
P11	AE	III	unmethyl.	supratentorial	subtotal	RT	TMZ	1	AE	TMZ	9	SD	9	10	13
P11	AE	III	unmethyl.	III ventricle	subtotal	RT	TMZ	1	AE	TMZ	9	SD	9	10	13
P12	AE	III	n.d.	supratentorial	subtotal	TMZ/RT → TMZ	re-resection	>3	AE	TMZ/RT → TMZ	5	SD	4	5	48
P12	AE	III	n.d.	parietal	subtotal	TMZ/RT → TMZ	bevacizumab	>3	AE	TMZ/RT → TMZ	5	SD	4	5	48
P13	AE	III	unmethyl.	supratentorial	gross total	RT	re-resection	3	AE	PCV	8	SD	1	5	40
P13	AE	III	unmethyl.	parietal	gross total	RT	PCV	3	AE	PCV	8	SD	1	5	40
P14	AE	III	unmethyl.	supratentorial	biopsy	-	re-resection	2	AE	TMZ	1	PD	-	2	2
				temporal			RT
				III ventricle			TMZ
P15	AE	III	methyl.	infratentorial	partial	RT	re-resection	3	AE	carboplatin	n.d.	PD	-	4	29^b
				cerebellar						etoposide
				brainstem
				IV ventricle
P16	AE	III	methyl.	supratentorial	n.d.	RT	PCV	1	AE	PCV	3	SD	2	6	39
P16	AE	III	methyl.	temporal	n.d.	RT	PCV	1	AE	PCV	3	SD	2	6	39
P17	AE	III	methyl.	supratentorial	subtotal	TMZ/RT → TMZ	bevacizumab	1	AE	TMZ/RT → TMZ	1	PD	-	1	6
P17	AE	III	methyl.	parietal	subtotal	TMZ/RT → TMZ	bevacizumab	1	AE	TMZ/RT → TMZ	1	PD	-	1	6

AE anaplastic ependymoma, CR complete response, DBR duration best response, E ependymoma WHO grade II; unmethyl., unmethylated, MGMT status O ⁶ -methylguanyl-DNA-methyltransferase promoter methylation status, n.d. no data, no. number, OS overall survival, P patient, PCV procarbazine/lomustine/vincristine, PD progressive disease, PFS progression-free survival, PR partial response, RT radiotherapy, SD stable disease, TMZ temozolomide
^a in months; ^b indicates patients who did not demonstrate progressive disease decease or who were not deceased, ^c median age was 28 years (range 18–56), 3 female and 14 male patients were included

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com